The Effects of Nebulized Budesonide and Dexamethasone on Patients Using Tube for Ventilation.

Effect of Nebulized Budesonide and Intravenous Dexamethasone on Tracheal Tube Cuff Leak in Intubated Patients Admitted to Intensive Care Unit

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017061734598N1

Enrollment

270

Registered

2017-09-15

Start date

2011-12-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Head trauma. Condition 2: Loss of Consciousness. Condition 3: Surgery. Condition 4: Poisoning. Crushing injury of head, part unspecified Coma, unspecified Complication of surgical and medical care, unspecified Drugs affecting uric acid metabolism

Interventions

Intervention 1: Control group: receiving 2 ml intravenous normal saline per 8 hours as well 4 ml normal saline per 12 hours through nebulizer. Intervention 2: Intervention group 2: receiving a dosage

Treatment - Other

Control group: receiving 2 ml intravenous normal saline per 8 hours as well 4 ml normal saline per 12 hours through nebulizer.

Intervention group 2: receiving a dosage of 8 mg intravenous dexamethasone per 8 hours for 48 hours and receiving 4ml normal saline every 12 hours through nebulizer as well.

Intervention group 1: receiving a dosage of 1mg in 4cc of nebulized budesonide every 12 hours (for 48 hours), each time for 20 minutes and 2 ml intravenous normal saline every 8 hours as well.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: the age range of 65-18 years; at least 48 hours of intubation; admission to intensive care unit and patient or his family’s consent to participate in the study. Exclusion criteria: receiving corticosteroids; respiratory disease such as asthma or chronic lung disease; chronic consumption of NSAIDs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Oxygen saturation. Timepoint: At the beginning of the study (zero hour) and 12, 24, 36 and 48 hours after intubation. Method of measurement: Pulse oximetry device.;Mean Arterial Pressure. Timepoint: At the beginning of the study (zero hour) and 12, 24, 36 and 48 hours after intubation. Method of measurement: Cardiac monitoring.;Heart Rate. Timepoint: At the beginning of the study (zero hour) and 12, 24, 36 and 48 hours after intubation. Method of measurement: Cardiac monitoring.;Cuff Leak Rate. Timepoint: At the beginning of the study (zero hour) and 12, 24, 36 and 48 hours after intubation. Method of measurement: (Average volume of exhaust flow at 3 breaths with low current volume - Current volume of the device)/Current volume of the device =CLR.	—

Measure

Time frame

Oxygen saturation. Timepoint: At the beginning of the study (zero hour) and 12, 24, 36 and 48 hours after intubation. Method of measurement: Pulse oximetry device.;Mean Arterial Pressure. Timepoint: At the beginning of the study (zero hour) and 12, 24, 36 and 48 hours after intubation. Method of measurement: Cardiac monitoring.;Heart Rate. Timepoint: At the beginning of the study (zero hour) and 12, 24, 36 and 48 hours after intubation. Method of measurement: Cardiac monitoring.;Cuff Leak Rate. Timepoint: At the beginning of the study (zero hour) and 12, 24, 36 and 48 hours after intubation. Method of measurement: (Average volume of exhaust flow at 3 breaths with low current volume - Current volume of the device)/Current volume of the device =CLR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Abbas Emami nejaad

Isfahan University of Medical Sciences

abbas_emaminejad@yahoo.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026